Retina is particularly susceptible to ischaemic damage following exposure to anoxia or hypoglycaemia. In animal models the neuronal damage following ischaemia resembles that caused by exposure to glutamate or other excitotoxic agents which act on excitatory amino acid receptors. There are a number of pharmacological approaches designed to limit neuronal damage following ischaemia. These include free radical scavenging agents, calcium channel blockers, kappa opiate agonists and excitatory amino acid antagonists. Recent studies with antagonists acting at both NMDA and non-NMDA receptors for glutamate show that such compounds can pro tect against ischaemic damage, and are effective even when administered several hours after the ischaemic insult.
Retinal neurones, like those in other regions of CNS, are highly dependent on the oxida tive metabolism of glucose for their energy requirements, and are susceptible to damage under conditions of ischaemia or hypoglycae mia. There has been an increased research effort in recent years devoted to the develop ment of pharmacological agents which might protect neural tissue against such damage. A wide variety of different scientific approaches has been used, and new compounds in development as potential 'neuroprotectives' include amino steroids and other free radical scavengers, calcium channel blockers, kappa opiate agonists, and excitatory amino acid antagonists (for reviews see [1] [2] [3] . This short review will focus on the latter category of new drugs, where considerable scientific progress has been made recently.
The Excitoxic Hypothesis
The neurotoxic effects of L-glutamate and L-aspartate were first described by Lucas and Newhouse4 33 years ago. They found that systemic administration of L-glutamate or aspartate in very large doses (2-4 g/kg s.cut) lead to profound neurodegenerative changes in retinal neurones of albino mice. These changes were seen mainly in ganglion cells in adult animals, but in immature animals all ret inal cells were affected. Olney and colleagues more than a decade later noted that system ically administered L-glutamate caused neu rode generative changes in basal hypothalamus and circumventricular regions of immature rat brain, and Olney was the first to formulate the hypothesis that L-glutamate and other neurotoxins which act to excite nerve cells owe their toxicity to their excitant properties. 5, 6 It is now generally recognised that L-glutamate and L-aspartate are widely used excitatory neurotransmitters in mamma lian CNS.b,7 In retina they are the principal transmitters used by excitatory inter-neu rones (bipolar cells, some amacrine cells and probably most ganglion cells).
A further extension of the excitotoxin hypothesis suggests that neural damage fol- lowing ischaemia or hypoglycaemia may result partly as a consequence of increased release of glutamate and/or over stimulation of excitatory amino acid receptors during such conditions.8.9
Excitatory Amino Acid Antagonists as Neuroprotective Agents .
L-glutamate and related excitants act on seva b� eral different receptors in eNS. At least three major receptor sub-types are recognised: the N-methyl-D-asparate preferring (NMDA) receptor, the quisqualate/kainate receptor (activated selectively by these agonists) and a 'metabotropic' quisqualate preferring recep tor, in which recognition of agonist is coupled to breakdown of membrane phosphoinosi tides. The first two receptors control cation channels, allowing the entry of sodium or sodium and calcium (NMDA) to depolarise target neurones (Fig. 1) . A range of anatogonists acting at the NMDA receptor have been described; these include competitive antagonists of the amino phosphonate series, and non-competitive antagonists. The most potent of the latter is the research compound MK -801 (dizocilpine) (Fig. 2) , others include the intravenous anaes thetics ketamine and p henc y clidine, and the A concentration of 0.1 �M MK-801 wa able to offer complete protection in this model. (Fig. 3) .
Other experiments have attempted to sim ulate conditions of ischaemia and/or hypo glycaemia in vitro. Choi and colleagues have used primary cultures of mouse cortical neu rones for such studies, and exposed them to a brief period of hypoxia (4-6h) or to glucose free medium. The damage which ensued appeared to be mediated largely by excitoxic mechanisms, since MK-801 and other NMDA antagonists provided complete protection in this in vitro model. The EC50 for MK-801 was 0.1 �M. 15 Zeevalk and Nicklas used 13 day old chick embyro retina in vitro and simulated hypoglycaemia and ischaemia by adding iodoacetate or potassium cyanide respect ively.16 Again MK -801 afforded complete pro tection, whereas the non-NMDA antagonist CNQX was ineffective. Olney et al. 17 however reported that in chick embryo retina a combi nation of MK-801 with CNQX was more effective than either compound alone in pro tecting against ischaemic damage, suggesting a possible involvement of both NMDA and non-NMDA receptors. The involvement of excitotoxic mechanisms in mediating retinal damage after ischaemia was strongly sug gested by the findings of David et al.18 who found that damage elicited by exposure of chick embryo retina to a 40 minute period of hypoxia could be largely prevented by addition of the non-selective glutamate antagonist gamma-glutamylglycine. Levy and Lipton19 have described an in vitro model using rat ret inal ganglion cells in culture, and found that the damage elicited by exposure to elevated external calcium concentrations (10 mM) was prevented by addition of NMDA antagonists, suggesting mediation by glutamate. They found that addition of MK-801 could be delayed for 4 h after initial exposure to ele vated calcium, and still remain neuroprotec tive. Other studies using a variety of in vivo models of cerebral ischaemia or exitotoxin induced damage to hippocampal or cortical neurones have also revealed a delayed effi cacy of MK-801 in offering neuroprotection, suggesting a possible clinical utility of this or related NMDA antagonists in the acute treat ment of stroke, prenatal-ischemia or other forms of cerebral ischaemia or hypoglycaemia (for reviews see [20] [21] .
The excitatory amino acid antagonists represent a promising new approach to the development of neuroprotective agents, although it is too soon to judge whether the effectiveness of such compounds in labora tory models will translate into clinical practice.
